Function Health’s unicorn moment (and lurking competition)news2025-11-20T20:12:09+00:00November 20th, 2025|Endpoints News|
Novartis, Moderna detail manufacturing expansions in the US, among othersnews2025-11-20T17:56:16+00:00November 20th, 2025|Endpoints News|
Abbott’s $21B diagnostic deal; Job cuts at Applied Therapeutics and AbbVienews2025-11-20T16:38:35+00:00November 20th, 2025|Endpoints News|
Dispatches from Jefferies: Why Alkermes wants Avadel, Light Chain’s hope for CD47, and morenews2025-11-20T16:33:02+00:00November 20th, 2025|Endpoints News|
AbbVie, Novartis can proceed with legal fight against Utah 340B lawnews2025-11-20T15:40:44+00:00November 20th, 2025|Endpoints News|
FDA will allow email ‘clarifications’ after pharma company meetingsnews2025-11-20T14:34:56+00:00November 20th, 2025|Endpoints News|
Flagship and portfolio companies do deals with GSK, Merck KGaA and Saudi Arabianews2025-11-20T14:27:08+00:00November 20th, 2025|Endpoints News|
FDA approves new indication and monthly dose of Regeneron’s Eylea HDnews2025-11-20T14:14:22+00:00November 20th, 2025|Endpoints News|
Aspen gets $115M for Parkinson’s cell therapy, potential IPO in sight next yearnews2025-11-20T12:02:48+00:00November 20th, 2025|Endpoints News|
Post-Hoc Live: The drug industry’s Mr. Reality Check, Derek Lowenews2025-11-20T12:00:14+00:00November 20th, 2025|Endpoints News|
